News Related to Cerevel Therapeutics

Related coverage linked through entity extraction aliases.

AbbVie raises 2026 guidance as Skyrizi and Rinvoq drive growth

May 05, 2026

AbbVie raised 2026 revenue and EPS guidance after first-quarter results beat estimates, with Skyrizi and Rinvoq driving growth. Humira erosion continued as neuroscience, oncology and pipeline assets supported the outlook.

AbbVie's Pipeline Growth and Dividend Track Record Draw Long-Term Investors

Mar 05, 2026

AbbVie has successfully transitioned from Humira dependence to growth driven by Skyrizi and Rinvoq, while maintaining a 54-year dividend increase streak and expanding its pipeline to roughly 90 programs through strategic acquisitions.